Novo Nordisk gains 7% on Q1 beat: is it too late to buy NVO stock?
Novo Nordisk’s rebound got another lift on Wednesday after the Danish drugmaker delivered a first-quarter beat and showed that its new Wegovy pill is gaining traction faster than Wall Street...


